Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04157478
Recruitment Status : Not yet recruiting
First Posted : November 8, 2019
Last Update Posted : November 11, 2019
Sponsor:
Collaborators:
First Affiliated Hospital of Guangxi Medical University
Cancer Hospital of Guangxi Medical University
Liuzhou Worker's Hospital
Nanxishan Hospital
Liuzhou People's Hospital
Affiliated Hospital of Guilin University
Information provided by (Responsible Party):
Heming Lu, People's Hospital of Guangxi

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2024